News
Insilico Develops The World’s First Fully AI-Generated Drug
The Abu Dhabi-based company hopes to treat idiopathic pulmonary fibrosis, and has 30 more drugs in the pipeline.
In a busy biotech hub in Abu Dhabi’s Masdar City, Insilico Medicine is pushing the frontiers of science. Under the watchful eye of Latvian-born CEO Dr Alex Zhavoronkov, the company has developed an AI-generated drug to treat idiopathic pulmonary fibrosis (IPF) — a deadly disease of the lungs.
“This AI drug is a major milestone for us and the industry as a whole,” Dr. Zhavoronkov explains. “We can use AI to create lifesaving treatments for new diseases using approaches we haven’t yet considered and do so much more rapidly and efficiently”.
Idiopathic pulmonary fibrosis is characterized by scarring of the lungs and has no known cure. Insilico’s AI drug aims to halt or even reverse the progression of IPF and is currently undergoing Phase 2 clinical trials in the US and China. The success of these trials will pave the way for more in-depth testing, bringing the drug closer to mass market approval.
Insilico’s groundbreaking research was recently published in Nature Biotechnology. It highlights how the company’s AI platform, Pharma.AI, is connecting the dots between fibrosis and aging to drive forward the discovery of a cure.
IPF treatment is just the beginning for Insilico. The company already has a roadmap consisting of over thirty AI-designed drugs, with seven already in clinical patient trials. These include treatments for inflammatory bowel disease, immuno-oncology targets, and even drugs developed using a method that targets a protein in cancers that can kill them without harming healthy cells.
Also Read: Personalized Supplement Company Bioniq Raises $15M In Funds
Dr Zhavoronkov’s ultimate goal is to leverage AI to unravel the complex processes involved in aging. “Our number one priority is to teach AI to understand the basic biology of aging, and I think we’ve succeeded in that process. Now, we need to demonstrate that we can utilize this understanding to cure diseases,” he says.
Insilico Medicine’s AI-driven drugs showcase the massive untapped potential of artificial intelligence in all aspects of healthcare. As the company continues to innovate, its work brings hope to patients around the world and demonstrates that the future of medicine is promising, thanks to the application of the latest technological breakthroughs.